Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatm… Read more
Aldeyra The (ALDX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.143x
Based on the latest financial reports, Aldeyra The (ALDX) has a cash flow conversion efficiency ratio of -0.143x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.02 Million) by net assets ($49.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aldeyra The - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Aldeyra The's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aldeyra The Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aldeyra The ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ezwelfare Co Ltd
KQ:090850
|
0.020x |
|
Unifi Inc
NYSE:UFI
|
0.110x |
|
CIKARANG LISTRINDO RP 200
F:B2O
|
N/A |
|
NeoVolta Inc. Warrant
NASDAQ:NEOVW
|
-1.169x |
|
Mortech Corporation
TWO:7419
|
-0.031x |
|
Akwel SA
PA:AKW
|
0.048x |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
-0.123x |
|
Soechi Lines Tbk
JK:SOCI
|
0.031x |
Annual Cash Flow Conversion Efficiency for Aldeyra The (2011–2024)
The table below shows the annual cash flow conversion efficiency of Aldeyra The from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.00 Million | $-43.21 Million | -0.609x | -140.38% |
| 2023-12-31 | $119.80 Million | $-30.33 Million | -0.253x | +32.50% |
| 2022-12-31 | $151.01 Million | $-56.64 Million | -0.375x | -81.32% |
| 2021-12-31 | $205.74 Million | $-42.56 Million | -0.207x | +67.17% |
| 2020-12-31 | $59.51 Million | $-37.49 Million | -0.630x | +32.66% |
| 2019-12-31 | $48.08 Million | $-44.98 Million | -0.936x | -171.42% |
| 2018-12-31 | $86.62 Million | $-29.86 Million | -0.345x | +28.99% |
| 2017-12-31 | $39.60 Million | $-19.22 Million | -0.485x | +30.62% |
| 2016-12-31 | $21.65 Million | $-15.15 Million | -0.700x | -86.93% |
| 2015-12-31 | $24.88 Million | $-9.31 Million | -0.374x | +50.75% |
| 2014-12-31 | $6.28 Million | $-4.78 Million | -0.760x | +28.08% |
| 2013-12-31 | $1.61 Million | $-1.71 Million | -1.057x | -3516.77% |
| 2012-12-31 | $-25.15 Million | $-778.05K | 0.031x | -96.98% |
| 2011-12-31 | $-2.33 Million | $-2.39 Million | 1.025x | -- |